AKRO — Akero Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $4.32bn
- $3.61bn
- 28
- 27
- 77
- 39
Annual cashflow statement for Akero Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -79.2 | -101 | -112 | -152 | -252 |
| Depreciation | |||||
| Non-Cash Items | 6.3 | 11.3 | 23.9 | 13 | 18.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.08 | 9.73 | -4.46 | -6.67 | 3 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -70.8 | -79.7 | -92.5 | -145 | -230 |
| Capital Expenditures | -0.148 | 0 | — | — | -0.999 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -9.61 | 42.3 | -63.8 | -224 | -109 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -9.76 | 42.3 | -63.8 | -224 | -110 |
| Financing Cash Flow Items | 0.052 | -0.521 | -0.469 | -0.776 | -0.844 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 203 | 0.602 | 256 | 353 | 446 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 123 | -36.8 | 99.3 | -15.7 | 106 |